Análisis de la acción iRhythm Holdings, Inc (IRTC)IRTCiRhythm Holdings, Inc

iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

iRhythm Technologies Inc is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $108.66, with a forward P/E ratio of 90.91, indicating high expectations for future earnings. However, the stock has a significant year-to-date decline of 37.99% and a 1-year change of -40.38%, which raises concerns about its short-term recovery potential. The recent insider activity shows a neutral stance, while hedge funds have increased their selling by 281.11% over the last quarter, suggesting a lack of confidence in the near-term outlook. The main risk is the substantial downgrade from Wells Fargo, which lowered its price target from $168 to $150, reflecting concerns about future revenue growth and market competition.

4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.